republic-os/legislation/us/states/va/2026/hb-1214.md

type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags

type	title	description	jurisdiction	legislature	session	identifier	citation	classification	subjects	status	primary_sponsors	version_count	action_count	vote_count	first_action	last_action	source	source_identifier	source_url	source_hash	vintage	source_snapshot	retrieved_at	confidence	tags
Bill	Health insurance; cost-sharing payments for insulin and diabetes equipment and supplies, limit.	Health insurance; cost-sharing payments for insulin and diabetes equipment and supplies; limit. Decreases the cap on the cost-sharing payment that a covered person is required to pay for a covered prescription insulin drug from $50 to $35 for a 30-day supply of the prescription insulin drug and provides such cap is an aggregate cap that applies in situations where the covered person is prescribed more than one insulin drug. The bill also establishes such an aggregate cap of $35 for a 30-day supply of diabetes equipment and supplies.	us/states/va	Virginia General Assembly	2026	HB 1214	Virginia HB 1214 (2026)	bill		enacted	Karrie K. Delaney	4	33	10	2026-01-14	2026-04-13	openstates	ocd-bill/48114462-fb3b-4b9d-a78b-76599da56e0a	https://lis.virginia.gov/bill-details/20261/HB1214	fc5b5aa3750c73f311df85c345c3151ad4f9561bab4dfb1d0108ed3859c8b322	2026-07-01	https://data.openstates.org/daily/2026-07-01/public.pgdump	2026-07-06	reported	legislation bill us-va

Virginia HB 1214 (2026) — Health insurance; cost-sharing payments for insulin and diabetes equipment and supplies, limit.

Health insurance; cost-sharing payments for insulin and diabetes equipment and supplies; limit. Decreases the cap on the cost-sharing payment that a covered person is required to pay for a covered prescription insulin drug from $50 to $35 for a 30-day supply of the prescription insulin drug and provides such cap is an aggregate cap that applies in situations where the covered person is prescribed more than one insulin drug. The bill also establishes such an aggregate cap of $35 for a 30-day supply of diabetes equipment and supplies.

Version chain

The bill's text revisions, in order — the diff chain from filing to enrollment.

1. Introduced (filed) — source
2. Commerce and Labor Amendment (committee substitute) — source
3. Senate Amendment (committee substitute) — source
4. Enrolled (enrolled) — source

Votes

• Reported from Commerce and Labor with amendment — 15–0 (pass) · upper
• Constitutional reading dispensed (on 2nd reading) — 37–0 (pass) · upper
• Passage R — 39–0 (pass) · upper
• Reconsider R — 40–0 (pass) · upper
• H VOTE: — 97–0 (pass) · lower
• Reported from Labor and Commerce — 22–0 (pass) · lower
• Passage R — 40–0 (pass) · upper
• Subcommittee recommends reporting — 9–0 (pass) · lower
• H VOTE: — 96–0 (pass) · lower
• H VOTE: — 98–0 (pass) · lower

Sponsors

• Karrie K. Delaney — primary (person)
• Adele Y. McClure — cosponsor (person)
• Elizabeth B. Bennett-Parker — cosponsor (person)
• Kathy K.L. Tran — cosponsor (person)
• Marcia S. "Cia" Price — cosponsor (person)
• Rozia A. Henson, Jr. — cosponsor (person)

Timeline

The legislative action history — every referral, reading, and vote.

• 2026-01-14 Prefiled and ordered printed; Offered 01-14-2026 26101381D filing, introduction
• 2026-01-14 Referred to Committee on Labor and Commerce referral-committee
• 2026-01-27 Assigned HCL sub: Subcommittee #1 referral-committee
• 2026-02-03 Subcommittee recommends reporting (9-Y 0-N)
• 2026-02-05 Reported from Labor and Commerce (22-Y 0-N) committee-passage
• 2026-02-09 Read first time reading-1
• 2026-02-10 Read second time and engrossed reading-2
• 2026-02-11 Read third time and passed House (96-Y 0-N 0-A) passage, reading-3
• 2026-02-11 Reconsideration of passage agreed to by House
• 2026-02-11 Passed House (98-Y 0-N 0-A) passage
• 2026-02-12 Constitutional reading dispensed (on 1st reading)
• 2026-02-12 Referred to Committee on Commerce and Labor referral-committee
• 2026-02-17 Fiscal Impact Statement from State Corporation Commission (HB1214)
• 2026-03-09 Senate committee offered
• 2026-03-09 Reported from Commerce and Labor with amendment (15-Y 0-N) committee-passage
• 2026-03-10 Rules suspended
• 2026-03-10 Constitutional reading dispensed (on 2nd reading) (37-Y 0-N 0-A)
• 2026-03-10 Passed by for the day (Voice Vote)
• 2026-03-11 Read third time reading-3
• 2026-03-11 Commerce and Labor Amendment agreed to amendment-passage
• 2026-03-11 Engrossed by Senate as amended
• 2026-03-11 Passed Senate with amendment Block Vote (39-Y 0-N 0-A) passage
• 2026-03-11 Reconsideration of Senate passage agreed to by Senate Block Vote (40-Y 0-N 0-A)
• 2026-03-11 Passed Senate with amendment Block Vote (40-Y 0-N 0-A) passage
• 2026-03-12 Senate amendment agreed to by House (97-Y 0-N 0-A) amendment-passage
• 2026-03-30 Enrolled enrolled
• 2026-03-30 Bill text as passed House and Senate (HB1214ER) passage
• 2026-03-30 Signed by President passage
• 2026-03-31 Signed by Speaker passage
• 2026-03-31 Enrolled Bill communicated to Governor on March 31, 2026 enrolled, executive-receipt
• 2026-03-31 Governor's Action Deadline 11:59 p.m., April 13, 2026 executive-receipt
• 2026-04-13 Fiscal Impact Statement from State Corporation Commission (HB1214)
• 2026-04-13 Approved by Governor-Chapter 752 (effective 7/1/2026) executive-signature

Source

OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/48114462-fb3b-4b9d-a78b-76599da56e0a. Confidence: reported (aggregated from official Virginia legislature records).